Transgenomic

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.
Type
Public
HQ
Omaha, US
Founded
1997
Size (employees)
37 (est)
Transgenomic was founded in 1997 and is headquartered in Omaha, US

Transgenomic Office Locations

Transgenomic has offices in Omaha and New Haven
Omaha, US (HQ)
12325 Emmet St
New Haven, US
5 Science Park

Transgenomic Metrics

Transgenomic Financial Metrics

Revenue (2015)

$1.7 m

Revenue growth (2014-15), %

(94%)

Gross profit

($287 k)

Gross profit margin (2015), %

(17%)

Net income (2015)

($33 m)

Market capitalization (28-Apr-2017)

$9.9 m

Closing share price (28-Apr-2017)

$0.4

Cash (31-Dec-2015)

$444 k
Transgenomic's current market capitalization is $9.9 m.
Transgenomic's revenue was reported to be $1.7 m in FY, 2015 which is a 94% decrease from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$27.5 m$27.1 m$1.7 m

Revenue growth, %

(2%)(94%)

Cost of goods sold

$15 m$17.4 m$1.9 m

Gross profit

$12.5 m$9.7 m($287 k)

Gross profit Margin, %

45%36%(17%)

Operating expense total

$28.3 m$27 m$8.9 m

EBIT

($15.8 m)($17.3 m)($9.2 m)

EBIT margin, %

(57%)(64%)(556%)

Interest expense

($642 k)($665 k)($724 k)

Interest income

($642 k)($665 k)($724 k)

Pre tax profit

($16 m)($13.4 m)($10.1 m)

Income tax expense

($54 k)$524 k

Net Income

($16 m)($13.9 m)($33 m)
FY, 2013FY, 2014FY, 2015

Cash

$1.6 m$1.6 m$444 k

Accounts Receivable

$5.3 m$7.6 m$264 k

Inventories

$4 m$3 m

Current Assets

$11.8 m$13.4 m$3.3 m

PP&E

$2 m$1.5 m$259 k

Goodwill

$6.9 m$6.9 m

Accounts Payable

$2.9 m$4.9 m$3.8 m

Current Liabilities

$8.6 m$11.1 m$17 m

Additional Paid-in Capital

$179.5 m$189.7 m$200.4 m

Retained Earnings

($168.5 m)($183.6 m)($213.4 m)
FY, 2013FY, 2014FY, 2015

Net Income

($16 m)($13.9 m)($33 m)

Depreciation and Amortization

$2.7 m$2.2 m$489 k

Accounts Receivable

($2.8 m)($8.5 m)$133 k

Inventories

$908 k$715 k($113 k)

Accounts Payable

$801 k$2 m($365 k)

Cash From Operating Activities

($2.9 m)($17 k)($12.4 m)

Purchases of PP&E

($605 k)($130 k)($204 k)

Cash From Investing Activities

($1.8 m)

Interest Paid

$724 k$229 k$493 k

Transgenomic Market Value History

Transgenomic Online Presence

Transgenomic Company Life

You may also be interested in